Medicine and Dentistry
Neoplasm
100%
Ganglioglioma
47%
Glioblastoma
36%
Pediatrics
28%
Intracranial Tumor
28%
Neurofibromatosis Type I
22%
Malignant Peripheral Nerve Sheath Tumor
22%
Meningioma
21%
Overall Survival
20%
Diseases
19%
Diagnosis
18%
Surgery
17%
Tumor Progression
16%
Central Nervous System
15%
Breast Cancer
14%
Neuroepithelioma
13%
Central Nervous System Tumor
12%
Radiation Therapy
11%
Microglia
11%
Gene Mutation
10%
Epidermal Growth Factor Receptor
10%
Magnetic Resonance Imaging
10%
Metastatic Carcinoma
10%
Ependymoma
10%
Tumor Cell
10%
Recurrent Disease
10%
Carcinogenesis
9%
Immunotherapy
8%
Papilloma
7%
Targeted Therapy
6%
Germ Cell
6%
Biopsy Technique
6%
Protein Expression
6%
Plexiform Neurofibroma
6%
Morphology
6%
Melanoma
6%
T Cell
6%
Oligoastrocytoma
6%
Cerebrospinal Fluid
6%
Malignant Neoplasm
5%
Connective Tissue Cancer
5%
Progression Free Survival
5%
Cancer
5%
Protein P53
5%
Metastatic Melanoma
5%
Transcriptional Regulator ATRX
5%
Choroid Plexus Papilloma
5%
Tuberous Sclerosis
5%
Subependymal Giant Cell Astrocytoma
5%
Cancer Growth
5%
Keyphrases
Tumor
70%
Glioblastoma
44%
Neurofibromatosis Type 1 (NF-1)
36%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
29%
Neurofibromatosis Type I
28%
Glioma
24%
Meningioma
24%
Brain Tumor
19%
Overall Survival
19%
Central Nervous System Tumors
15%
Histopathological Features
14%
Low-grade Glioma
12%
Pediatric Glioma
12%
Tumor Growth
11%
Pediatric
11%
Germ Cells
11%
BRAF V600E mutation
10%
Central Nervous System
10%
Copy number Variation
10%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Clinical Features
10%
Genetic Modification
9%
Glioma Growth
9%
Tumor Cells
9%
Molecular Diagnostics
8%
Tumor Protein p53 (TP53)
8%
ATRX mutation
8%
Knockdown
8%
Cerebrospinal Fluid
8%
Clinical Outcomes
8%
Optic Pathway Glioma
8%
BRAF Alteration
8%
Subventricular Zone
8%
HOXB13
8%
Temporal Lobe
8%
Progression-free Survival
7%
Recurrence-free Survival
7%
Resection
7%
Microglia
7%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
7%
Targeted Therapy
7%
BRAF Inhibitor (BRAFi)
7%
Diffuse Glioma
7%
Ependymoma
7%
Prognostic Marker
7%
Pilocytic Astrocytoma
7%
Ganglioglioma
7%
CNS Tumors
7%
Non-neoplastic
7%
Genomic Profiling
6%